Key result
Data from multiple registries and cohorts underscore the importance of quality indicators and risk stratification, noting nearly 20% of children with repaired PAH-CHD died within ten years.
Answers are grounded in this paper and cite their sources.
Provides a broad overview of contemporary cardiovascular research, emphasizing the implementation of precision medicine, advanced imaging, and quality indicators to improve patient outcomes.
Arterial hypertension remains a prevalent and serious global health challenge, with up to one-third of patients failing to achieve adequate blood pressure control.1 Emerging precision medicine strategies, including RNA-targeted therapeutics, offer promising long-acting and highly specific treatment options, particularly for resistant hypertension. These subcutaneous therapies may improve adherence and blood pressure control; however, evidence regarding their impact on cardiovascular outcomes, organ protection, and mortality is still lacking.2 Pulmonary arterial hypertension (PAH) may persist, recur, or develop after congenital heart disease (CHD) repair, even following timely surgery. Validated paediatric risk stratification tools are lacking, and adult PAH scores are often unsuitable. Data from a large national cohort show that nearly 20% of children with repaired PAH-CHD died within ten years despite widespread therapy. A simple four-variable risk score, based on routine clinical parameters (absence of pre-operative pulmonary hypertension, breathlessness, right ventricular systolic dysfunction, and high pulmonary vascular resistance index or high-risk lesion) and externally validated, enables early prognostic assessment and may guide treatment intensity and follow-up.3 Adults with CHD who develop heart failure face complex lifelong challenges that are insufficiently captured by existing outcome measures. A qualitative study highlights the need for co-designed, disease-specific health-related quality-of-life instruments, identifying key psychosocial domains currently underrepresented.4 These findings support a more holistic, person-centred care approach aligned with contemporary guidelines. Enterococcal infective endocarditis is increasingly prevalent, particularly among older, comorbid patients and those with prior healthcare exposure.5 Analysis from the EURO-ENDO registry shows that these patients are more likely to have prosthetic valves and worse clinical profiles.6 Early surgery and advanced imaging, including PET, were associated with improved outcomes. Optimizing care pathways may reduce relapse rates and improve survival. Fabry disease is a rare X-linked lysosomal storage disorder with significant cardiac involvement. Advances in cardiac magnetic resonance imaging have improved understanding of disease mechanisms. A multiparametric CMR-based risk score, including T1 mapping, effectively predicts adverse cardiovascular outcomes.7 Patients with normal myocardial T1 values have a very low event risk, underscoring the prognostic value of non-invasive myocardial tissue characterization. Transcatheter aortic valve implantation (TAVI) is an increasingly important treatment for aortic stenosis.8 European Society of Cardiology quality indicators for TAVI9 were shown to be feasible using registry data and were independently associated with all-cause and cardiovascular mortality. These indicators represent a valuable tool for benchmarking performance and improving patient outcomes.10 Acute heart failure remains a leading cause of morbidity and mortality, with substantial clinical and economic burden. Data from the French OFICA2 multicentre cohort identified key predictors of poor outcomes and highlighted gaps in care pathways, including suboptimal discharge planning, underuse of guideline-directed medical therapy, and insufficient specialist follow-up.11 Acetazolamide, when added to loop diuretics, improves early decongestion in acute heart failure. Cost-effectiveness modelling based on the ADVOR trial demonstrated that acetazolamide is both more effective and less costly than standard therapy, primarily by reducing hospital length of stay, with substantial potential savings at a national level.12 Postoperative atrial fibrillation is common arrhythmias,13,14 with incidence following coronary artery bypass grafting. Real-world data from a national registry indicate lower thromboembolic mortality among patients receiving oral anticoagulation, although long-term survival beyond 30 days did not differ significantly. These findings support consideration of time-limited anticoagulation strategies in this setting.15 None declared.
No takes yet. Share an insight, caveat, or question.
Mascolo et al. (2026) conducted a review in Heart failure and predisposing cardiovascular conditions. Data from multiple registries and cohorts underscore the importance of quality indicators and risk stratification, noting nearly 20% of children with repaired PAH-CHD died within ten years.
Synapse has enriched 10 related papers. Consider them for comparative context: